Quantitative Investment Management LLC Buys New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Quantitative Investment Management LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, Holdings Channel reports. The firm purchased 11,712 shares of the medical equipment provider’s stock, valued at approximately $1,008,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $25,000. Tacita Capital Inc acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $26,000. Ancora Advisors LLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $29,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet during the fourth quarter worth about $30,000. Finally, Gen Wealth Partners Inc bought a new position in Zimmer Biomet during the fourth quarter worth about $31,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 0.5%

Zimmer Biomet stock opened at $99.52 on Wednesday. The stock has a market cap of $18.98 billion, a P/E ratio of 24.21, a P/E/G ratio of 1.89 and a beta of 0.47. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $106.88. The company’s 50-day moving average price is $94.38 and its two-hundred day moving average price is $91.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the previous year, the company posted $2.07 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ZBH shares. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Canaccord Genuity Group increased their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Royal Bank Of Canada raised their price target on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, Sanford C. Bernstein lifted their price objective on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.